Nureca P/E Ratio
Nureca (NURECA) P/E ratio is 24.19 (Moderate), EPS (TTM) ₹0.85, current price ₹271.80 on NSE vs historical average P/E of 19.48 (50.0th percentile) — High - Growth expectations or overvalued. For live price, revenue and the complete fundamental profile, see Nureca share price chart.
Current Valuation Metrics
Valuation Signal
Sector Context
Earnings Breakdown (TTM)
NURECA P/E Ratio — Valuation Signal & Historical Context
Nureca P/E 24.19 vs historical average 19.48, range 12.68–26.28 — signal: Overvalued. Analyse Nureca ownership structure to track promoter, FII and institutional holdings.
- Current PE is 24.2% above historical average
- Trading at discount to sector average PE of 50.02
Nureca P/E Ratio Historical Trend
NURECA annual price-to-earnings ratio — 2 years, EPS and year-end price. Current P/E 24.19 vs historical average 19.48. Browse NURECA complete financial statements for revenue, profit, balance sheet and cash flow data.
NURECA Historical P/E Ratio — EPS, Year-End Price & Valuation
Nureca annual P/E ratio, EPS (₹), year-end price and valuation category on NSE.
| Year | P/E Ratio | EPS (₹) | Year-end Price (₹) | Exchange | Valuation |
|---|---|---|---|---|---|
| 2025 | 26.28 | 10.82 | ₹284.30 | NSE | High |
| 2021 | 12.68 | 50.92 | ₹645.75 | NSE | Low |
NURECA vs Healthcare Peers — P/E Ratio Comparison
Nureca P/E 24.19 vs Healthcare average 50.02, median 29.4 — range 1.0–869.57.
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 1.0 | ₹36 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.45 | ₹61 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.69 | ₹1,161 | Low |
| Amwill Health Care | AMWILL | 6.34 | ₹65 | Low |
| Brooks Laboratories | BROOKS | 6.6 | ₹137 | Low |
| Mono Pharmacare | MONOPHARMA | 7.1 | ₹21 | Low |
| Shelter Pharma | SHELTER | 7.4 | ₹54 | Low |
| Medicamen Organics | MEDIORG | 7.51 | ₹32 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹66 | Low |